Sun Bo, Zhang Lijie, Xiang Dongqiao, Li Qing, Ren Yanqiao, Cao Yanyan, Sun Tao, Zhang Weihua, Wu Linxia, Zhu Licheng, Chen Lei, Zhao Huangxuan, Zheng Chuansheng
Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Hubei Province Key Laboratory of Molecular Imaging, Wuhan 430022, China.
J Oncol. 2022 Dec 30;2022:7062105. doi: 10.1155/2022/7062105. eCollection 2022.
Alcohol consumption can increase the risk of developing hepatocellular carcinoma (HCC). However, whether continuous alcohol consumption can influence outcomes in patients with HCC who undergo transarterial chemoembolization (TACE) remains unclear. This study aimed to explore the effect of alcohol consumption in patients with unresectable HCC who underwent TACE.
The data used in the study were obtained from two centers and were retrospectively reviewed between January, 2014, and December, 2021. 254 patients with TACE were included in this study. Among them, 101 patients were continuous alcohol consumers and 153 patients had alcohol abstinence. Propensity score matching (PSM) and competing risk analysis were used to reduce the selection bias.
The median overall survival (mOS) and median progression-free survival (mPFS) in the alcohol consumers' group were longer than those in the alcohol abstinence group, before and after PSM. Multivariate regression analysis showed that alcohol consumption increased all-cause mortality risk (HR: 1.486, 95% CI: 1.074-2.055; =0.016) and tumor progression risk (HR: 1.434, 95% CI: 1.091-1.886; =0.01) more than that with alcohol abstinence. In the competing risk analysis, after excluding deaths caused by other reasons, alcohol consumption increased cancer-specific mortality risk more than alcohol abstinence did before and after PSM. Adverse event analysis showed that alcohol consumption increased the risk of all grades of nausea and vomiting and grade III or IV nausea more than alcohol abstinence did after patients underwent TACE.
Alcohol consumption may lead to a poor prognosis and increase adverse events in patients receiving TACE compared to those with alcohol abstinence.
饮酒会增加肝细胞癌（HCC）的发病风险。然而，持续饮酒是否会影响接受经动脉化疗栓塞术（TACE）的HCC患者的预后仍不清楚。本研究旨在探讨饮酒对接受TACE的不可切除HCC患者的影响。
本研究使用的数据来自两个中心，对2014年1月至2021年12月期间的数据进行回顾性分析。本研究纳入了254例接受TACE治疗的患者。其中，101例患者持续饮酒，153例患者戒酒。采用倾向评分匹配（PSM）和竞争风险分析来减少选择偏倚。
在PSM前后，饮酒组的中位总生存期（mOS）和中位无进展生存期（mPFS）均长于戒酒组。多因素回归分析显示，饮酒比戒酒更能增加全因死亡风险（HR：1.486，95%CI：1.074-2.055；P=0.016）和肿瘤进展风险（HR：1.434，95%CI：1.091-1.886；P=0.01）。在竞争风险分析中，排除其他原因导致的死亡后，饮酒比戒酒更能增加PSM前后的癌症特异性死亡风险。不良事件分析显示，患者接受TACE治疗后，饮酒比戒酒更能增加所有等级恶心呕吐以及III级或IV级恶心的风险。
与戒酒患者相比，饮酒可能导致接受TACE治疗的患者预后不良，并增加不良事件的发生。
